Bone marrow transplantation and organ transplantation studies suggest that bone marrow cells can differentiate into a variety of non-hematological tissues, including renal cells. The results of a number of experimental animal studies also showed that cell therapy (bone marrow cells [BMCs], hematopoietic stem cells [HSCs], mesenchymal stem cells [MSCs]) might have the potential to rescue animals from organ injuries. However, when BMCs or HSCs were injected into rodents subjected to ischemic or toxininduced acute tubular necrosis (ATN), the results with regard to whether they could rescue rodents from ATN were inconsistent. The reasons for the conflicting results of BMC or HSC therapy in ATN are unknown, but may be due to the different types of cells injected, number of cells injected, route of injection, or injury model of acute renal failure. It is known that MSCs can contribute to renal tubular regeneration after ATN, although the exact mechanism, either transdifferentiation or effects of paracrine/cytokines, is uncertain. In the future, the most pertinent issue is to determine how MSCs protect the renal tubule from injury, and then to imitate this protective or reparative effect pharmacologically.
Introduction
Acute renal failure (ARF) is defined as a rapid decline in glomerular filtration rate (GFR) occurring within hours or days, resulting in the failure of the kidney to excrete nitrogen waste products, and failure to maintain extracellular fluid volume, electrolyte and acidbase homeostasis [1] [2] [3] [4] . Definitions of ARF range from a slight rise in serum creatinine concentration (e.g. of 0.5 mg/dL) to severe ARF status (i.e. that requiring dialysis). Although there is no universal laboratory definition, it is reasonable to define ARF as a rise in serum creatinine levels for 2 weeks or less of 0.5 mg/dL (44. 2 μmol/L) if the baseline is less than 2.5 mg/dL, or a rise in serum creatinine levels by more than 20% if the baseline is more than 2.5 mg/dL [4] . ARF may occur in three clinical settings: (1) as a result of severe volume depletion and hypotension without compromising the integrity of renal parenchyma (prerenal ARF); (2) obstruction to the urinary tract (postrenal ARF); and (3) diseases that directly affect renal parenchyma (intrinsic renal ARF). Prerenal ARF can be corrected if the extrarenal factors causing the renal hypoperfusion are reversed. In addition, an obstructive cause of ARF must be excluded because prompt intervention can lead to improvement or complete recovery of renal function. Acute tubular necrosis (ATN), resulting from prolonged renal hypoperfusion and renal ischemia or nephrotoxic substances, is a pathological diagnosis. Pathophysiologically, ATN is associated with tubular cell death and shedding into the tubular lumen, resulting in tubular blockage, further reducing glomerular filtration. Despite major advances in intensive care, renal replacement therapy, and exploration of cellular and molecular pathogenesis of ARF, no specific therapy is currently available. Consequently, the overall mortality rate of patients with ARF is still high, about 50% in a recent series [3, 5, 6] , and has changed little during the past 30 years. Therefore, a more powerful therapeutic intervention for ATN to decrease mortality rate is imperative. Recently, a number of studies have provided evidence that bone marrow stem cells (BMSCs) may have a great potential to rescue people from organ injury. Here, we introduce the present studies on BMSCs in patients with renal diseases and discuss the future direction for applying BMSCs to renal regeneration.
Stem cells

Totipotent, pluripotent and multipotent
A stem cell is defined as a cell from the embryo, fetus, or adult that is capable of self-renewal over long periods and differentiation to one or more types of specialized cells under certain conditions [7] . Competent levels of stem cells can be classified as either totipotent (able to contribute to all three embryonic germ layers as well as extraembryonic tissues), pluripotent (giving rise to all three germ layers of the embryo), or multipotent (with the potential to differentiate into multiple cell types, but not derivatives of all three germ layers).
Embryonic stem cells
Embryonic stem (ES) cells are derived from the inner cell masses of the blastocysts and are pluripotent [8] .
The pluripotent character of ES cells may provide therapeutic potential for many disorders. However, there are still several issues remaining unresolved about using ES cells from human embryos and applying them to clinical applications, including uncontrolled growth of inappropriate tissue types, rejection complications, and ethical issues.
Adult stem cells
In adult organisms, each tissue and organ are believed to contain a small subpopulation of cells, i.e. tissuespecific stem cells that remain committed to support their own family of descendants. Hemato poietic stem cells (HSCs) are the best characterized; this knowledge has allowed therapeutic grafting to make a tremendous impact on hematological malignancy and offers great promise for hemoglobinopathies and other genetic diseases [9] . A recent study showed in vitro expanded renal-derived CD133 + cells homed into the injured kidney and integrated into tubules. However, it cannot be excluded that these CD133 + cells might have been contaminated from the blood of renal microcirculation because these cells were directly obtained from the cortex without pre-infusion with isotonic sodium chloride solution [10] . Therefore, do renal stem cells exist in the adult kidneys? Most researchers agree that the kidney should contain organ-specific stem cells like other adult organs, but no researchers claim they can recognize functional renal stem cells either by location or by characteristic morphology or surface mole cule expression [11, 12] .
BMSCs and their therapeutic potential
Plasticity of BMSCs
BMSCs are a many-faceted population and have been classified as HSCs, marrow stromal cells (or MSCs), multipotent adult progenitor cells (MAPCs), and side population (SP) cells [13] . Bone marrow transplantation (BMT) is an existing mode of stem cell therapy for patients with blood disorders such as leukemia.
More than four decades of accomplished in vivo BMT studies have clarified the activities of a rare BMSC that is both self-renewing and multipotent in its ability to give rise to all blood cell types and provide recipients with long-term repopulating cells [9] . Traditionally, adult stem cells were believed to be lineage-restricted and organ-specific. Therefore, it was not thought possible that stem cells derived from bone marrow could not only rescue patients with hematological disorders but also extricate non-hematopoietic tissues from organ damage, i.e. the existence of stem cell plasticity had not been recognized. The first significant report alerting to the possibility of stem cell plasticity was published by Ferrari et al [14] who transplanted bone marrow cells (BMCs) into recipient mice and subsequently injured the muscles of these recipient animals. Surprisingly, donor cell nuclei were found incorporated into the regenerated skeletal muscle at a frequency of approximately 0.01%. Now, a growing number of studies based on simple BMT protocols have claimed that adult BMSCs can differentiate into a variety of non-hematological tissues in rodents, such as skeletal muscle [14] , astrocytes [15] , osteoblasts [16] , endothelial cells [17] , cardiomyocytes [18] , neuronal cells [19, 20] , hepatocytes [21] , epidermal cells [22] , pneumocytes [22, 23] , renal tubular epithelium and podocytes [24] , and gut cells [22, 25] . Likewise, in humans, bone marrow can apparently differentiate into hepatocytes [26, 27] , renal tubular cells [24] , epithelium of the skin [27] , skeletal muscle [28] , cardiomyocytes [29] , epithelia of gastrointestinal tract [27, 30] , respiratory tract [31] , and neurons [32, 33] .
Cell fusion between BMCs and differentiated cells in engrafted organs
Although some researchers have questioned stem cell plasticity and showed this is really the result of the fusion of BMCs with the differentiated cells in the engrafted organ including hepatocytes [34] [35] [36] , Purkinje cells [36, 37] , cardiomyocytes [36] and skeletal muscle cells [38, 39] , a number of studies have demonstrated that cell fusion is not a major player in the transdifferentiation of BMCs into various specific cell types (reviewed in [40, 41] ).
Therapeutic potential of BMCs for extrarenal diseases
Through the establishment of bone marrow chimerism, a few successful cases of HSC transplantation in utero have rescued patients with severe combined immunodeficiency disease, β-thalassemia, and Bloom's syndrome [42, 43] . Moreover, the results of a series of studies have shown the possibility that bone marrow grafting could act as cell therapy for nonhematological diseases, such as osteogenesis imperfecta [44] [45] [46] . Horwitz et al [44] showed that BMT improved certain parameters of patients with osteogenesis imperfecta, and stromal cell cultures from bio psies of recipient bones indicated that donorderived cells were present. A subsequent study showed that further administration of mesenchymal cells cultured from the same donor gave some further improvement of clinical parameters due to the formation of functional wild-type osteoblasts from the donor mesenchymal cells, although gene-marked cells when detectable were < 1% of cells in bone cultures [46] . Recently, experimental and early clinical studies have supported the concept that autologous bone marrow infusions were beneficial in chronic limb ischemia [47] , ischemic heart disease [48] , and myocardial infarction [49, 50] in humans, although the benefits appeared to be related to preserving or re-establishing microvessels and limiting the extent and severity of the damage [51] .
Engraftment of BMCs as renal cells
Table 1 [22, 24, shows the potential of BMCs to transdifferentiate into renal cells according to the study results of cross-sex BMT and kidney transplantation.
Engraftment of BMCs as renal vessels and interstitium
Considering the renal vessels and interstitium, the results of early studies of renal vascular engraftment by Williams et al [52, 53] and Sinclair [54] showed, based on cross-sex renal transplant studies, that repopu lated endothelium of vessels may be derived from circulating cells when chronic rejection of allografts occurred. Williams et al reported that 10% of the endothelium in allografts of the kidney and aorta could be from the host marrow when chronic rejection of allografts occurred, and engraftment was less when rejection was attenuated by immunosuppression [52, 53] . Sinclair [54] counted Barr bodies in 40 male patients with female renal transplants and showed donor endothelium persisted in 37 of 40 cases, but not in three patients with grafts that were very poorly functioning and severely damaged. How ever, Andersen et al [55] examined kidney specimens from 40 sexmismatched transplant patients clinically suggested of developing acute rejection, and reported that there was no evidence of revascularization by recipient endothelial cells; furthermore, tubular and glomerular cells remained of donor origin in the transplanted kidneys with acute rejection, even 10 months after transplantation. Recently, the results of two studies showed that vascular endothelium [58, 61] and tubulointerstitial cells [58] were of host origin when allografts of human kidneys show chronic rejection. The percentage of engraftment of vascular endothelium of host origin was more than 33% in the majority of patients (86%) with vascular rejection [58, 61] . Similarly, the percentage of vascular endothelium of host origin was 34-76% in allografts with vascular rejection, and the percentage of interstitial cells of host origin was 30-77% in allografts with interstitial rejection [58] . These results suggest circulating mesenchymal precursors reside within the bone marrow and migrate to vessels or interstitial areas when allograft rejection occurs. However, the results from a study by Iwano et al showed that interstitial kidney Table 1 fibroblasts were derived not only from bone marrow but also from local tubular epithelium [64] .
-Summary of the potential of bone marrow cells to transdifferentiate into renal cells according to the studies of cross-sex bone marrow transplantation and kidney transplantation
Engraftment of BMCs as glomerular mesangial cells and podocytes
Turning to glomerular mesangial cells and podocytes, Poulsom et al and Sugimoto et al demonstrated that BMCs contributed to podocyte regeneration and amelio ration of renal disease in a mouse model of Alport syndrome [24, 77, 79] . Regarding mesangial cells, Cornacchia et al demonstrated that mesangial cell progenitors may carry a disease genotype and that the phenotype can be transmitted after BMT [57] . Several studies also showed that BMCs differentiated into glomerular mesangial cells in rodents with and without glomerular injury [59, 60, 63, 68, 78] . More over, Masuya et al reported that transplantation of a single HSC could generate numerous glomerular mesangial cells [67] .
Engraftment of BMCs as renal tubular epithelium
Considering renal tubular epithelium, Poulsom et al demonstrated that BMSCs contributed to both normal turnover of renal epithelium in mice and the level of engraftment in renal tubular cells was 3-8%, and regeneration after damage in humans where the level of engraftment in renal tubular cells was 1.8-20% [24] . Animal studies from our group and other groups also showed that BMCs contributed to renal regeneration after ATN [70, 71] . However, not all reports were compatible with these studies. Krause et al showed that no donor-derived renal tubule epithelial cells were seen in any of the five mice transplanted with a single highly selected HSC, perhaps ineffective due to the use of a sorted HSC rather than the whole bone marrow [22] . However, it is unknown whether epithelial chimerism is an incidental by-product of cross-gender BMT and renal allografts without biological meaning or whether alternatively the process plays a role in kidney repair. For example, Gupta et al reported that 1% of tubules contained male epithelial cells in two male patients with female kidney allografts and ATN, however, no male epithelial cells were noted in two cases without ATN, suggesting that recipient-derived cells do not routinely repopulate the transplanted kidney [62, 80] . These findings contrast with recent observations by Mengel et al who showed that chimeric tubular epithelial cells (2.4-6.6%) occurred regularly in allografts, and was not correlated with outcome [69] .
The results of our recent study demonstrated that BMCs contributed to the renal tubular epithelial cell population and regenerated renal tubular epithelium after ARF via cell proliferation [70] . Table 2 [66, 73, [81] [82] [83] [84] [85] [86] [87] [88] shows the conflicting results of BMC therapy for acute renal injury. The reasons for the conflicting results of BMC therapy in acute renal injury are unknown, but may be due to the different types of injected cells, number of injected cells, route of injection, or injury model of ARF.
Therapeutic potential of BMC therapy for ATN
Whole BMC therapy for ATN
It is still conflicting whether whole BMCs can contribute to tubular regeneration after ATN [66, 85] . For example, Kale et al demonstrated that the engraftment of renal tubular cells of the outer medulla from BMCs increased from 3.0 ± 0.1% to 20.9 ± 1.6% after ischemia-reperfusion (I/R) renal injury [66] , sugges ting a major contribution of BMCs to functional repair of the ischemically injured tubule. However, the results of another study showed that BMCs did not improve renal function after I/R renal injury, although a rise in engraftment of tubular epithelial cells, glomerular cells and interstitial cells was seen [85] .
HSC therapy for ATN
With regard to HSC therapy for ATN, it is still uncertain. For example, Lin et al studied female non-transgenic mice subjected to 11 Gray γ-irradiation 2 hours before the left renal artery was clamped for 15 minutes, and 2000 Rh lo Lin -Sca-1 + ckit + HSCs from male ROSA26 mice were injected into the female mice within hours after the unilateral renal I/R injury [81] . Four weeks after I/R renal injury, HSC-derived tubular epithelium was seen only with ischemic damage, and the percentage of Y chromosome-positive cells in the regenerating renal proximal tubules was 8.3 ± 3.2%. However, Dekel et al showed that human BM CD34 + HSCs when injected into NOD/SCID mice subjected to I/R renal injury via renal pelvis could not improve renal function and these cells could not acquire a tubular phenotype [87] .
MSC therapy for ATN
With regard to MSC therapy for ATN, it is established that MSCs can contribute to regeneration of renal tu bules after ATN, although the exact mechanism is controversial. There are at least two possible mechanisms for MSCs to rescue ATN: transdifferentiation of MSCs into renal tubule cells and paracrine and/ or angiogenic effects of MSCs. However, it is not known which one is more important. For example, two studies demonstrated that MSCs, when injected into non-irradiated mice subjected to cisplatin-induced or glycerol-induced ATN, could rescue mice from acute tubular damage and differentiate into renal tubular epithelium [82, 83] . However, the results of other studies showed that the administration of MSCs via carotid artery either immediately or 24 hours after renal ischemia [73, 84, 86] or via either tail veins or left renal artery 1 day after anti-Thy1.1 nephritis induction [88] , significantly improved renal function through a change in the cytokine milieu or paracrine growth factor release, but not because of their transdifferentiation into renal tubular cells. The reason for the discrepant results of MSC transdifferentiation into renal epithelial cells between these two kinds of studies is unclear.
In fact, MSCs not only release angiogenic (vascular endothelial growth factor) and anti-inflammatory cytokines (transforming growth factor β1), but MSCs also have strong immunosuppressive activity [89] . However, it is still conflicting if administration of MSCs to people subjected to ATN can develop a neo-expressing protein and may induce an immune response. For example, several studies demonstrated that MSCs had shown strong immunosuppressive activity [89] , and modulated the immune response via modifying the cytokine response of dendritic cells and T cells, via interfering with the development of immunocompetent dendritic cells, and via favoring the development of regulatory T cells [90, 91] . In contrast, one recent study showed that the administration of allogeneic donor MSCs primed naïve T cells and hastened rejection of the bone marrow, whereas recipient autologous MSCs promoted tolerance and acceptance of transplants [92] .
Conclusion
Studies of tissue from recipients of BMT or organ allografts suggest that BMCs can differentiate into a variety of non-hematological tissues, including renal cells. However, it is uncertain whether BMCs or HSCs, when injected into rodents subjected to ischemic or toxin-induced ATN, could rescue rodents from ATN. The reasons for the conflicting results of BMC or HSC therapy in ATN are unknown, but may be dependent on the different types of injected cells, number of injected cells, route of injection, or injury model of ARF. MSCs could contribute to renal tubular regeneration after ATN, although the exact mechanism, either transdifferentiation of MSCs or effects of paracrine/ cytokines, is uncertain. In the future, the most pertinent issue is to determine exactly how MSCs protect the renal tubule from injury, and then to imitate this protective or reparative effect pharmacologically. If the primary role of MSCs is to secrete a cytokine or growth factor in response to injury, then the cells themselves might not be essential, and we should be able to recognize the factor or factors and either administer it directly or establish pharmacological policy to stimulate its production by endogenous cells.
